Semin Thromb Hemost 2000; Volume 26(Number 01): 085-090
DOI: 10.1055/s-2000-9808
Copyright © 2000 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4663)

Effects of β2-Glycoprotein I and Monoclonal Anticardiolipin Antibodies on Extrinsic Fibrinolysis

Masahiro Ieko1 , Kenji Ichikawa2 , Tatsuya Atsumi2 , Rie Takeuchi2 , Ken-Ichi Sawada2 , Taro Yasukouchi3 , Takao Koike2
  • 1Department of Internal Medicine, School of Dentistry, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido, Japan
  • 3Institude of Health Sciences, Health Sciences University of Hokkaido, Ishikari-Tobetsu, Hokkaido, Japan;
  • 2Department of Medicine II, Hokkaido University School of Medicine, Sapporo, Japan
Further Information

Publication History

Publication Date:
31 December 2000 (online)

 

ABSTRACT

Antiphospholipid antibodies (aPLs) are associated with an increased incidence of thrombosis, but the mechanisms responsible for thrombosis are unclear. The present study investigated the effect of both β2-glycoprotein I (β2-GPI) and aPLs on the activity of extrinsic fibrinolysis. The remaining tissue-plasminogen activator (t-PA) of the sample consisting of β2-GPI, two-chain recombinant t-PA, plasminogen activator inhibitor (PAI) -1 was measured by a chromogenic assay using synthetic substrate S-2251, Glu-plasminogen, and soluble fibrin monomer. Without PAI-1, β2-GPI did not affect t-PA activity. When 14.3 ng/ml PAI-1 was added to 3.6 U/ml t-PA, the remaining t-PA activity was increased from 48.9% to 60.4% by the addition of β2-GPI (190 μg/ml). The effect of β2-GPI did not require phospholipids. The β2-GPI seems to protect t-PA activity from the inhibition by PAI-1. When monoclonal anticardiolipin antibodies (aCLs), EY1C8, and EY2C9, which were established from a patient with antiphospholipid syndrome, were further added to the mixture with a diluted phospholipid (Platelin®) to investigate the influence of aPL, the remaining t-PA activity decreased to 50.1 and 80.7%. Monoclonal aCLs appeared to inhibit the effect of β2-GPI, that is, these monoclonals inhibited the fibrinolytic activity by an elevation in PAI-1 activity. These results suggest the possibility that the impairment of fibrinolytic activity by aCLs is one of reasons for the increased incidence in thrombosis in patients with aCLs.

KEYWORD

β2-Glycoprotein I - tissue-plasminogen activator (t-PA) - plasminogen activator inhibitor-1 (PAI-1) - monoclonal anticardiolipin antibody - chromogenic assay

REFERENCES

  • 1 Marciniak E, Romond E H. Impaired catalytic function of activated protein C: A new in vitro manifestation of lupus anticoagulant.  Blood . 1989;  74 2426-2432
    CrossrefPubMedGoogle Scholar
  • 2 Malia R G, Kicken S, Greaves M, Prestone F E. Inhibition of activated protein C and its cofactor protein S by antiphospholipid antibodies.  Br J Haematol . 1990;  76 101-107
    CrossrefPubMedGoogle Scholar
  • 3 Oosting J D, Derksen R W M H, Bobbink I WG. Antiphospholipid antibodies directed against a combination of phospholipids with prothrombin, protein C, or protein S: An explanation for their pathogenic mechanism.  Blood . 1993;  81 2618-2615
    CrossrefPubMedGoogle Scholar
  • 4 Pötzsch B, Kawamura H, Preissner K T. Acquired protein C dysfunction but not decreased activity of thrombomodulin is a possible marker of thrombophillia in patients with lupus anticoagulant.  J Lab Clin Med . 1995;  125 56-65
    PubMedGoogle Scholar
  • 5 Reverter J C, Tassies D, Font J. Effect of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes.  Arthritis Rheumatol . 1998;  41 1420-1427
    CrossrefPubMedGoogle Scholar
  • 6 Branch D W, Rodgers G M. Induction of endothelial cell tissue factor activity by sera from patients with antiphospholipid syndrome: A possible mechanism of thrombosis.  Am J Obstet Gynecol . 1993;  168 206-210
    CrossrefPubMedGoogle Scholar
  • 7 Yamazaki M, Asakura H, Jokaji H. Plasma levels of lipoprotein (a) are elevated in patients with the antiphospholipid antibody syndrome.  Thromb Haemost . 1994;  71 424-427
    PubMedGoogle Scholar
  • 8 Ames P J, Tomashino C, Iannaccone L. Coagulation activation and fibrinolytic imbalance in subjects with idiopathic antiphospholipid antibodies-a crucial role for acquired free protein S deficiency.  Thromb Haemost . 1996;  76 190-194
    PubMedGoogle Scholar
  • 9 Heimburger N, Heide K, Haupt H, Schultz H E. Bausteinanalysen von Human Serum Proteinen.  Clin Chim Acta . 1964;  10 293-302
    CrossrefPubMedGoogle Scholar
  • 10 McNeil H P, Simpson R J, Chesterman C N, Krilis S A. Antiphospholipid antibodies are directed against a complex antigen that includes a lipid-binding inhibitor of coagulation: β2-glycoprotein I (apolipoprotein H).  Proc Natl Acad Sci USA . 1990;  87 4120-4124
    CrossrefPubMedGoogle Scholar
  • 11 Galli M, Comfurius P, Maassen C. Anticardiolipin antibodies (ACA) directed not to cardiolipin but to a plasma protein cofactor.  Lancet . 1990;  335 1544-1547
    CrossrefPubMedGoogle Scholar
  • 12 Matsuura E, Igarashi Y, Fujimoto M, Ichikawa K, Koike T. Anticardiolipin cofactor(s) and differential diagnosis of autoimmune disease.  Lancet . 1990;  336 177-178
    PubMedGoogle Scholar
  • 13 Nimpf J, Wurm H, Kostner G M. Interaction of β2 glycoprotein-I with human blood platelets: Influence upon ADP induced aggregation.  Thromb Haemost . 1985;  54 397-401
    PubMedGoogle Scholar
  • 14 Schousboe I. β2 glycoprotein I: A plasma inhibitor of the contact activation of the intrinsic blood coagulation pathway.  Blood . 1985;  66 1086-1091
    PubMedGoogle Scholar
  • 15 Nimpf J, Bevers E M, Bomans P HH. Prothrombinase activity of human platelets is inhibited by β2 glycoprotein-I.  Biochim Biophys Acta . 1986;  884 142-149
    PubMedGoogle Scholar
  • 16 Mori T, Takeya H, Nishioka J, Gabazza E C, Suzuki K. β2-Glycoprotein I modulates the anticoagulant activity of activated protein C on the phospholipid surface.  Thromb Haemost . 1996;  75 49-55
    PubMedGoogle Scholar
  • 17 Ichikawa K, Khamashita M A, Koike T, Matsuura E, Hughes G RV. β2-Glycoprotein I reactivity of monoclonal anticardiolipin antibodies from patients with the antiphospholipid syndrome.  Arthritis Rheum . 1994;  37 1453-1461
    CrossrefPubMedGoogle Scholar
  • 18 Rånby M, Wallén P. A sensitive parabolic assay for tissue plasminogen activator. In: Davidsson JF, Nilson IM, Astedt B, eds. Progression Fibrinolysis Vol. 5. Edinburgh: Churchill Livingstone, 1981: 233-235
    Google Scholar
  • 19 Shiozaki A, Niiya K, Higuchi F. Ellagic acid/phospholipid-induced coagulation and dextran sulfate-induced fibrinolytic activities in β2-glycoprotein I-depleted plasma.  Thromb Res . 1994;  76 199-210
    CrossrefPubMedGoogle Scholar
  • 20 Hughes G RV, Harris E N, Gharabi A E. The anticardiolipin syndrome.  J Rheumatol . 1986;  13 486-489
    PubMedGoogle Scholar
  • 21 Roubey R AS. Mechanisms of autoantibody-mediated thrombosis.  Lupus . 1998;  7 S114-S119
    CrossrefPubMedGoogle Scholar
  • 22 Takeya H, Mori T, Gabazza E C. Anti-β2-glycoprotein I (β2GPI) monoclonal antibodies with lupus anticoagulant-like activity enhance the β2GPI binding to phospholipids.  J Clin Invest . 1997;  99 2260-2268
    CrossrefPubMedGoogle Scholar
  • 23 Ieko M, Ichikawa K, Triplett D A. β2-Glycoprotein I is necessary to inhibit protein C activity by monoclonal anticardiolipin antibodies.  Arthritis Rheum . 1999;  42 167-174
    CrossrefPubMedGoogle Scholar
  • 24 Doig R G, O'Malley C J, Dauer R, McGrath K M. An evaluation of 200 consecutive patients with spontaneous or recurrent thrombosis for primary hypercoagulable states.  Am J Clin Pathol . 1994;  102 797-801
    PubMedGoogle Scholar
  • 25 Atsumi T, Khamashta M A, Andujar C. Elevated plasma lipoprotein(a) level and its association with impaired fibrinolysis in patients with antiphospholipid syndrome.  J Rheumatol . 1998;  25 69-73
    PubMedGoogle Scholar
  • 26 Loscalzo J, Weinfeld M, Fless G M, Scanu A M. Lipoprotein(a), fibrin binding, and plasminogen activation.  Arteriosclerosis . 1990;  10 240-245
    PubMedGoogle Scholar
  • 27 Etingin O R, Hajjar D P, Hajjar K A, Harpel P C, Nachman R L. Lipoprotein (a) regulates plasminogen activator inhibitor-1 expression in endothelial cells. A potential mechanism in thrombogenesis.  J Biol Chem . 1991;  266 2459-2465
    PubMedGoogle Scholar
      >